Biotechnology News
Biotechnology
US CAR-T focused biotech CARGO Therapeutics today announced that it has entered into a definitive merger agreement with Concentra Biosciences, initially worth roughly $200 million. The news sent CARGO’s stock up as much as 9.6% to $4.81 in pre-market activity. 8 July 2025
Biotechnology
An Expert View from Justin Kozak, life sciences industry lead, Founder Shield. 4 July 2025
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti CD38 monoclonal antibody. 3 July 2025
Most Read
Recent news
Biotechnology
Radiant Biotherapeutics, a Canadian biotech advancing multi-specific, multi-affinity antibody (Multabody) therapeutics in cancer and autoimmune diseases, has announced the appointment of Deborah Geraghty as president and chief executive. 9 July 2025
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies announced the formalization of an agreement with biologics manufacturing partner, Sweden’s NorthX Biologics, to accelerate the development of Nimivec, Amarna’s next-generation gene therapy platform targeting immune-mediated diseases. 9 July 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Kisunla (donanemab-azbt), Eli Lilly's once-monthly amyloid-targeting therapy for early symptomatic Alzheimer's disease (AD), including patients with mild cognitive impairment (MCI) and the mild dementia stage of AD, with confirmed amyloid pathology. 9 July 2025
Biotechnology
US clinical-stage biotech ProKidney reported statistically-significant and clinically-meaningful positive top-line results from the full Group 1 modified intent-to-treat (mITT) population of the Phase II REGEN-007 trial evaluating rilparencel in patients with CKD and diabetes. 9 July 2025
Biotechnology
Japan’s JCR Pharmaceuticals closed 15% higher after Wednesday’s trading, as it signed a new licensing deal. 9 July 2025
Refine Search
In Brief
Biotechnology
3 July 2025 Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics.
Biotechnology
19 June 2025 The benefits from Eli Lilly’s Kisluna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute for Health and Care Excellence (NICE), which also rejected Japanese drugmaker Eisai and US biotech Biogen Leqembi (lecanemab) for the same reason.
Insights
Biotechnology
Lupus is a rare autoimmune disease characterized by chronic inflammation. It presents in four main forms: systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), drug-induced lupus, and neonatal lupus. SLE is the most common, accounting for approximately 70% of cases. Unlike CLE, which affects only the skin, SLE can involve the skin, joints, connective tissue, and internal organs.1 28 May 2025
Biotechnology
Adopting a platform approach to designing new therapies will speed the delivery of innovative genomic treatments to patients—but only if developers, regulators, and manufacturers work together to evolve the current drug development paradigm, writes Vanessa Almendro, vice president of science and technology and head of innovation at Danaher Corporation, in an Expert View piece. 19 May 2025
Biotechnology
China's burgeoning biotech R&D capabilities are attracting increasing international attention, with non-Western countries actively seeking partnerships. At the BIOCHINA event in Suzhou on March 13, representatives from South Korean and Russian biotechs expressed strong interest in collaborating with Chinese counterparts. 21 March 2025
Biotechnology
The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment by a long stretch. That honor belonged to the whopping $410 million netted by UK obesity group Verdiva Bio, but what Orbis’s VC round does show is the growing interest in macrocyclics as a drug class. 6 February 2025
Biotechnology
In this Expert View column, Abbas Kazimi, chief business officer of Nimbus Therapeutics, discusses the advantages of a “failing fast” business strategy and the infrastructures and protocols that must be in place to support rapid, objective decision-making and portfolio management. 29 January 2025
Biotechnology
This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene. 16 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Boardroom
Radiant Biotherapeutics, a Canadian biotech advancing multi-specific, multi-affinity antibody (Multabody) therapeutics in cancer and autoimmune diseases, has announced the appointment of Deborah Geraghty as president and chief executive. 9 July 2025
US oncology-focused biotech Crescent Biopharma has appointed Jan Pinkas as chief scientific officer (CSO). 8 July 2025
Debra Barker has been named chief medical officer (CMO) at Centauri Therapeutics, a UK immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic indications. 8 July 2025
Diagonal Therapeutics, a US biotech focused on correcting dysregulated signaling with clustering antibodies that address the underlying cause of intractable genetic diseases, has announced the appointment of John Lee as chief medical officer (CMO). 8 July 2025
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze